Isolated Hepatocyte Transplantation in an Infant With a Severe Urea Cycle Disorder
Top Cited Papers
- 1 June 2003
- journal article
- case report
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 111 (6) , 1262-1267
- https://doi.org/10.1542/peds.111.6.1262
Abstract
Objective. Transplantation of isolated hepatocytes in animal models has been shown to correct inborn errors of metabolism. Based on these studies and our experience with hepatocyte transplantation in a child with Crigler-Najjar syndrome, isolated hepatocyte transplantation was performed to attempt metabolic reconstitution in a male infant with severe ornithine transcarbamylase (OTC) deficiency. Methods. An infant with an antenatal diagnosis of OTC deficiency was managed intensively to prevent hyperammonemia. Isolated hepatocytes were obtained by collagenase perfusion of donated livers not used for transplantation. Hepatocytes were infused in batches over the first 4 weeks of life via an umbilical venous catheter positioned in the portal vein. Immunosuppression consisted of tacrolimus and corticosteroids. Results. Over 4 billion viable hepatocytes were transplanted during the first 3.5 weeks of life. A period of metabolic stability was achieved between days 20 and 31 during which normal protein intake was tolerated while phenylbutyrate was weaned. During this time, plasma ammonia and glutamine remained within normal limits. Hyperammonemia reappeared abruptly on day 31 of life. Protein tolerance diminished to baseline; metabolic stability was subsequently reattained only following successful liver transplantation at 6 months of age. Conclusions. Isolated hepatocyte transplantation appeared to result in temporary relief of hyperammonemia and protein intolerance attributable to OTC deficiency. The metabolic stability achieved was lost after 11 days presumably because of rejection of the transplanted cells because of insufficient immunosuppression. Future attempts at isolated hepatocyte transplantation for inborn errors of metabolism in humans should include adequate immunosuppression and a liver biopsy as a means of proving hepatocyte engraftment and function.Keywords
This publication has 14 references indexed in Scilit:
- Hepatocyte transplantation as a treatment for glycogen storage disease type 1aThe Lancet, 2002
- Neurological outcome of patients with ornithine carbamoyltransferase deficiencyArchives of Disease in Childhood, 2002
- Auxiliary liver transplantation for urea-cycle enzyme deficiencies: lessons from three casesTransplantation Proceedings, 1999
- Long-term amerlioration of bilirubin glucuronidation defect in gunn rats by transplanting genetically modified immortalized autologous hepatocytesCell Transplantation, 1998
- Liver transplantation for the treatment of urea cycle disordersJournal of Inherited Metabolic Disease, 1998
- Treatment of the Crigler–Najjar Syndrome Type I with Hepatocyte TransplantationNew England Journal of Medicine, 1998
- Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type INature Genetics, 1996
- Orthotopic liver transplantation in liver-based metabolic disordersEuropean Journal of Pediatrics, 1992
- HEPATOCYTE TRANSPLANTATION FOR THE LOW-DENSITY LIPOPROTEIN RECEPTOR-DEFICIENT STATEATransplantation, 1990
- Hepatocellular Transplantation for Metabolic Deficiencies: Decrease of Plasma Bilirubin in Gunn RatsScience, 1976